JP4101876B2 - 抗炎症活性を有する脂質抽出物 - Google Patents
抗炎症活性を有する脂質抽出物 Download PDFInfo
- Publication number
- JP4101876B2 JP4101876B2 JP51149997A JP51149997A JP4101876B2 JP 4101876 B2 JP4101876 B2 JP 4101876B2 JP 51149997 A JP51149997 A JP 51149997A JP 51149997 A JP51149997 A JP 51149997A JP 4101876 B2 JP4101876 B2 JP 4101876B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- treatment
- oil
- lipid extract
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000284 extract Substances 0.000 title claims description 34
- 150000002632 lipids Chemical class 0.000 title claims description 32
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 27
- 239000000203 mixture Substances 0.000 claims description 41
- 238000011282 treatment Methods 0.000 claims description 32
- 206010003246 arthritis Diseases 0.000 claims description 25
- 239000004480 active ingredient Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 14
- 239000004006 olive oil Substances 0.000 claims description 14
- 235000008390 olive oil Nutrition 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 13
- 241001537210 Perna Species 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 239000003961 penetration enhancing agent Substances 0.000 claims description 6
- 229960005233 cineole Drugs 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 4
- 229930007050 cineol Natural products 0.000 claims description 3
- 239000010776 emu oil Substances 0.000 claims description 2
- 229940087305 limonene Drugs 0.000 claims description 2
- 235000001510 limonene Nutrition 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 125000003555 cineol group Chemical group 0.000 claims 1
- 241000237536 Mytilus edulis Species 0.000 description 25
- 235000020638 mussel Nutrition 0.000 description 19
- 241000700159 Rattus Species 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 238000003556 assay Methods 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 238000000605 extraction Methods 0.000 description 12
- 210000002683 foot Anatomy 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241001537211 Perna canaliculus Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 8
- 239000000679 carrageenan Substances 0.000 description 8
- 235000010418 carrageenan Nutrition 0.000 description 8
- 229940113118 carrageenan Drugs 0.000 description 8
- 229920001525 carrageenan Polymers 0.000 description 8
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010036030 Polyarthritis Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 208000030428 polyarticular arthritis Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000005995 Aluminium silicate Substances 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 235000012211 aluminium silicate Nutrition 0.000 description 4
- 230000002456 anti-arthritic effect Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003501 anti-edematous effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- -1 free fatty acids Chemical class 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 238000011020 pilot scale process Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000008524 evening primrose extract Nutrition 0.000 description 2
- 229940089020 evening primrose oil Drugs 0.000 description 2
- 239000010475 evening primrose oil Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 231100000420 gastrotoxicity Toxicity 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010012186 Delayed delivery Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 229940124347 antiarthritic drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000001387 apium graveolens Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009100 aurothiomalate Drugs 0.000 description 1
- XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- UGOFYAXVVVXMQT-UHFFFAOYSA-N clobuzarit Chemical compound C1=CC(COC(C)(C)C(O)=O)=CC=C1C1=CC=C(Cl)C=C1 UGOFYAXVVVXMQT-UHFFFAOYSA-N 0.000 description 1
- 229950007550 clobuzarit Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- YAHRDLICUYEDAU-UHFFFAOYSA-N methylhexaneamine Chemical compound CCC(C)CC(C)N YAHRDLICUYEDAU-UHFFFAOYSA-N 0.000 description 1
- 229950000752 methylhexaneamine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000010464 refined olive oil Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 229940119224 salmon oil Drugs 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 229960001315 sodium aurothiomalate Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPN5311A AUPN531195A0 (en) | 1995-09-11 | 1995-09-11 | Lipid extract having anti-inflamatory activity |
| AU5311 | 1995-09-11 | ||
| PCT/AU1996/000564 WO1997009992A1 (en) | 1995-09-11 | 1996-09-10 | Lipid extract having anti-inflammatory activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPH11512400A JPH11512400A (ja) | 1999-10-26 |
| JPH11512400A5 JPH11512400A5 (enExample) | 2004-09-16 |
| JP4101876B2 true JP4101876B2 (ja) | 2008-06-18 |
Family
ID=3789640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51149997A Expired - Lifetime JP4101876B2 (ja) | 1995-09-11 | 1996-09-10 | 抗炎症活性を有する脂質抽出物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6083536A (enExample) |
| EP (1) | EP0850068B1 (enExample) |
| JP (1) | JP4101876B2 (enExample) |
| AT (1) | ATE293984T1 (enExample) |
| AU (1) | AUPN531195A0 (enExample) |
| CA (1) | CA2231803C (enExample) |
| DE (1) | DE69634666T2 (enExample) |
| DK (1) | DK0850068T3 (enExample) |
| ES (1) | ES2241001T3 (enExample) |
| PT (1) | PT850068E (enExample) |
| WO (1) | WO1997009992A1 (enExample) |
| ZA (1) | ZA967626B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220131272A (ko) | 2020-01-21 | 2022-09-27 | 린트벨스 리미티드 | 상승효과가 있는 조성물 |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN531195A0 (en) * | 1995-09-11 | 1995-10-05 | J.W. Broadbent Nominees Pty. Ltd. | Lipid extract having anti-inflamatory activity |
| CN1265566A (zh) | 1997-06-04 | 2000-09-06 | 细胞改良有限公司 | 破碎生物材料的方法和装置 |
| SE9703085D0 (sv) * | 1997-08-27 | 1997-08-27 | Micro Active Protein In Sweden | Anti-microbial composition |
| US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
| US7220427B2 (en) | 1998-07-08 | 2007-05-22 | Oryxe | Mixture for transdermal delivery of low and high molecular weight compounds |
| DE19838794A1 (de) * | 1998-08-26 | 2000-03-09 | Aristavet Veterinaerspezialita | Zusammensetzung zur Behandlung von Osteoarthritis und zur nutritiven Behandlung des Gelenkknorpels |
| AUPP910699A0 (en) * | 1999-03-10 | 1999-04-01 | Pharmalink International Limited | Inhibitor of lipoxygenase pathways |
| US6596303B1 (en) * | 1999-03-22 | 2003-07-22 | Mars Incorporated | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals |
| AU2005200953B2 (en) * | 1999-03-22 | 2007-07-12 | Mars, Incorporated | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals and method of manufacturing same |
| US20020018787A1 (en) * | 1999-05-21 | 2002-02-14 | Roger V. Kendall | Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| EP1408999B1 (en) * | 1999-07-21 | 2008-03-12 | Bomac Research Limited | Compositions addressing inflammation and/or degenerative disorders |
| ATE270558T1 (de) * | 1999-08-26 | 2004-07-15 | Ganeden Biotech Inc | Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien |
| AUPR030800A0 (en) * | 2000-09-22 | 2000-10-12 | Pharmalink International Limited | Immunomodulatory preparation |
| AU9347701A (en) * | 2000-09-22 | 2002-04-02 | Pharmalink Internat Ltd | Immunomodulatory preparation |
| US7519546B2 (en) * | 2001-04-30 | 2009-04-14 | General Electric Company | Maintaining synchronization of information published to multiple subscribers |
| EP1417211B1 (en) | 2001-07-27 | 2007-05-30 | Neptune Technologies & Bioressources Inc. | Natural phospholipids of marine origin containing flavonoids and polyunsaturated phospholipids and their uses |
| AUPS082102A0 (en) * | 2002-03-01 | 2002-03-21 | Women's And Children's Hospital | Therapeutic properties of oils |
| WO2003077811A1 (en) * | 2002-03-14 | 2003-09-25 | Mcclung Jackie H | Pharmaceutically active compounds containing phosphorous defficient oil |
| DE20210182U1 (de) * | 2002-07-01 | 2002-10-02 | Bio-Innovation Development Ltd., Christchurch | Wirkstoffzusammensetzung aus Bestandteilen der Grünlippenmuschel (perna canaliculus) und zusätzlichen Omega-3-Fettsäuren |
| US20040228926A1 (en) * | 2003-03-14 | 2004-11-18 | Kendall Roger V. | Methods for treating cancer using perna canaliculus component(S) and extracts of perna canaliculus |
| US7052715B2 (en) * | 2003-04-11 | 2006-05-30 | All Natural Fmg, Inc. | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
| US7033998B2 (en) * | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| WO2005073354A1 (en) * | 2004-01-30 | 2005-08-11 | Bionovate Limited | Solvent extraction of lipids such as essential fatty acids |
| GB0411165D0 (en) * | 2004-05-19 | 2004-06-23 | Bionovate Ltd | Hyaluronic acid containing pharmaceutical or veterinary compounds |
| GB0411166D0 (en) * | 2004-05-19 | 2004-06-23 | Bionovate Ltd | Treatment for asthma and arthritis |
| US20060039992A1 (en) * | 2004-06-02 | 2006-02-23 | Miller Bruce A Jr | Novel compositions and methods utilizing green-lipped mussel and fatty acids |
| WO2006052150A1 (en) * | 2004-11-15 | 2006-05-18 | University Of Otago | Mussel extract composition with enhanced anti-inflammatory activity |
| US8092839B2 (en) * | 2004-12-13 | 2012-01-10 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| US8431165B2 (en) * | 2004-12-13 | 2013-04-30 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| WO2006128244A1 (en) * | 2005-06-03 | 2006-12-07 | Mc Farlane Marketing (Aust.) Pty. Ltd. | Lipid extract of mussels and method for preparation thereof |
| NZ547429A (en) * | 2006-05-24 | 2009-09-25 | Ind Res Ltd | Extraction of highly unsaturated lipids with liquid dimethyl ether |
| US20090238763A1 (en) * | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
| US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
| CN101489985B (zh) | 2006-07-18 | 2014-01-08 | 天津昕晨泰飞尔医药科技有限公司 | 具有快速皮肤穿透率的带正电荷的水溶性布洛芬前药 |
| PL2046727T3 (pl) | 2006-07-25 | 2014-08-29 | Techfields Biochem Co Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki diklofenaku o bardzo szybkim stopniu przenikania przez skórę |
| EP2990402A1 (en) | 2006-08-08 | 2016-03-02 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of aryl- and heteroarylacetic acids with very fast skin penetration rate |
| EP2061749B1 (en) | 2006-09-03 | 2018-02-21 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate |
| CN101506168B (zh) | 2006-09-03 | 2014-12-10 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性的芳基邻氨基苯甲酸的前药 |
| WO2008035756A1 (en) * | 2006-09-22 | 2008-03-27 | Heimat Co., Ltd. | Anti-angiogenic composition comprising extract having anti-angiogenic activity and lecithin |
| ES2466346T3 (es) * | 2006-10-02 | 2014-06-10 | Techfields Biochem Co. Ltd | Profármacos de prostaglandinas solubles en agua con carga positiva y compuestos relacionados con índices de penetración en la piel muy altos |
| JP5378221B2 (ja) | 2006-10-11 | 2013-12-25 | テックフィールズ バイオケム カンパニー リミテッド | 非常に高い皮膚浸透率を有するオキシカム及び関連化合物の正荷電水溶性プロドラッグ |
| NZ552238A (en) * | 2006-12-20 | 2009-07-31 | Seperex Nutritionals Ltd | An extract |
| US8337916B2 (en) * | 2007-06-01 | 2012-12-25 | Laila Nutraceuticals | Use of Aphanamixis polystacha extracts or fractions against 5-lipoxygenase mediated diseases |
| WO2008149181A1 (en) * | 2007-06-04 | 2008-12-11 | Techfields Inc | Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses |
| MX340963B (es) * | 2008-04-28 | 2016-07-29 | Vermont Italia Srl | Formulacion farmaceutica que contiene palmitoil etanolamida y estearoil etanolamida. |
| WO2010065936A1 (en) | 2008-12-04 | 2010-06-10 | Chongxi Yu | High penetration compositions and their applications |
| JP5313064B2 (ja) * | 2009-07-03 | 2013-10-09 | 株式会社ノエビア | 中性脂肪蓄積促進剤、豊胸剤 |
| CN104540504A (zh) | 2012-01-18 | 2015-04-22 | 苏州泰飞尔医药有限公司 | 治疗肺部疾病的高穿透力前药组合物和医药组合物 |
| SG11201505076UA (en) | 2012-12-31 | 2015-07-30 | Jrx Biotechnology Inc | Liquid topical pharmaceutical nano-emulsion formulations |
| JP6176655B2 (ja) * | 2013-07-02 | 2017-08-09 | 御木本製薬株式会社 | マトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤、老化防止用皮膚外用剤、シワ防止用皮膚外用剤、慢性関節リウマチ及び他の疾患の治療又は予防剤 |
| SG11201800440SA (en) * | 2015-07-20 | 2018-02-27 | Bengt I Samuelsson Institute Of Life Science Res | Mussel adhesive protein product and applications thereof in suppression of skin inflammations |
| KR20180053318A (ko) | 2015-09-17 | 2018-05-21 | 제이알엑스 바이오테크놀로지, 인코포레이티드 | 피부 수화 또는 보습을 향상시키기 위한 접근법 |
| AR110560A1 (es) * | 2016-12-20 | 2019-04-10 | Sanford Ltd | Extractos y/o composiciones bioactivas de mejillones |
| CN111432654A (zh) * | 2017-12-04 | 2020-07-17 | 雾凇科技有限公司 | 从甲壳类捕获物中生产蛋白质磷脂复合物的方法 |
| PL3727404T3 (pl) * | 2017-12-22 | 2024-01-29 | Pharmalink International Limited | Kompozycje zawierające ekstrakt lipidowy z małży i olej z kryla oraz ich zastosowania medyczne |
| CN113041263B (zh) * | 2021-03-15 | 2023-07-25 | 青岛大学 | 一种贻贝功能性脂质在制备治疗2型糖尿病产品中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2965855D1 (en) * | 1978-09-25 | 1983-08-18 | Farlane Stuart John Mc | Pharmaceutical preparations containing a mollusc extract |
| US4801453A (en) | 1984-05-01 | 1989-01-31 | James M. Broadbent | Stabilized mussel extract |
| AUPM740594A0 (en) | 1994-08-11 | 1994-09-01 | J.W. Broadbent Nominees Pty. Ltd. | Anti-inflammatory preparation |
| AU3156595A (en) * | 1994-08-11 | 1996-03-07 | J.W. Broadbent Nominees Pty. Ltd. | Anti-inflammatory preparation |
| AUPN531195A0 (en) * | 1995-09-11 | 1995-10-05 | J.W. Broadbent Nominees Pty. Ltd. | Lipid extract having anti-inflamatory activity |
-
1995
- 1995-09-11 AU AUPN5311A patent/AUPN531195A0/en not_active Abandoned
-
1996
- 1996-09-10 WO PCT/AU1996/000564 patent/WO1997009992A1/en not_active Ceased
- 1996-09-10 AT AT96929129T patent/ATE293984T1/de active
- 1996-09-10 PT PT96929129T patent/PT850068E/pt unknown
- 1996-09-10 ZA ZA9607626A patent/ZA967626B/xx unknown
- 1996-09-10 DK DK96929129T patent/DK0850068T3/da active
- 1996-09-10 EP EP96929129A patent/EP0850068B1/en not_active Expired - Lifetime
- 1996-09-10 JP JP51149997A patent/JP4101876B2/ja not_active Expired - Lifetime
- 1996-09-10 US US09/029,957 patent/US6083536A/en not_active Expired - Lifetime
- 1996-09-10 CA CA002231803A patent/CA2231803C/en not_active Expired - Lifetime
- 1996-09-10 DE DE69634666T patent/DE69634666T2/de not_active Expired - Lifetime
- 1996-09-10 ES ES96929129T patent/ES2241001T3/es not_active Expired - Lifetime
-
2000
- 2000-07-05 US US09/610,484 patent/US6346278B1/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220131272A (ko) | 2020-01-21 | 2022-09-27 | 린트벨스 리미티드 | 상승효과가 있는 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0850068A4 (en) | 2000-09-13 |
| ZA967626B (en) | 1997-09-03 |
| CA2231803C (en) | 2004-11-23 |
| ES2241001T3 (es) | 2005-10-16 |
| EP0850068B1 (en) | 2005-04-27 |
| US6083536A (en) | 2000-07-04 |
| US6346278B1 (en) | 2002-02-12 |
| CA2231803A1 (en) | 1997-03-20 |
| DE69634666T2 (de) | 2006-04-27 |
| JPH11512400A (ja) | 1999-10-26 |
| AUPN531195A0 (en) | 1995-10-05 |
| DE69634666D1 (de) | 2005-06-02 |
| PT850068E (pt) | 2005-08-31 |
| EP0850068A1 (en) | 1998-07-01 |
| DK0850068T3 (da) | 2005-08-15 |
| ATE293984T1 (de) | 2005-05-15 |
| WO1997009992A1 (en) | 1997-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4101876B2 (ja) | 抗炎症活性を有する脂質抽出物 | |
| RU2122409C1 (ru) | Лечение жирными кислотами | |
| JP3172177B2 (ja) | エミュー油から誘導した抗炎性混合物 | |
| EP0440341B1 (en) | EFA compositions and therapy | |
| US4874794A (en) | Inflammatory disease treatment | |
| EP0189788B1 (de) | Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika | |
| Pongprayoon et al. | Topical antiinflammatory activity of the major lipophilic constituents of the rhizome of Zingiber cassumunar. Part I: The essential oil | |
| JPS61215322A (ja) | γ‐リノレン酸またはジホモ‐γ‐リノレン酸の使用方法 | |
| NZ227241A (en) | Pharmaceutical compositions comprising a cyclosporin and either dihomo-gamma or gamma-linolenic acid and use in combatting the effects of cyclosporin administration | |
| US20140107206A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| EP0524796B1 (en) | Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS | |
| DE3907649C2 (de) | Arzneimittel, geeignet bei der Bekämpfung von Viren und zur Immunstimulierung | |
| JP2011067213A (ja) | 生物活性油 | |
| JPH04505758A (ja) | 即効で増強された解熱応答 | |
| AU616502B2 (en) | Treatment of inflammatory disorders in humans | |
| US5194451A (en) | Systemic anti-inflammatory treatment | |
| US5166219A (en) | Systemic anti-inflammatory treatment | |
| WO2014158256A1 (en) | Omega-3 pentaenoic acid compositions and methods of use | |
| CN105407885A (zh) | 包含ω-3脂肪酸和番茄的番茄红素的组合 | |
| JPH05500361A (ja) | 開始―促進され／増強された解熱応答 | |
| US20080274209A1 (en) | Methods of treating inflammation | |
| KR960700064A (ko) | 아연이 보충된 전립선 추출물 | |
| US5260067A (en) | Cytotropic heterogeneous molecular lipids (CHML) and process for preparing the same | |
| EP0381823A2 (en) | Cytotropic heterogenous molecular lipids (CHML) and process for preparing the same | |
| JP2018039769A (ja) | ウロリチン類を含有する前駆脂肪細胞分化抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070828 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071127 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080226 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080321 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120328 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130328 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130328 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140328 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |